Lantern Pharma Inc.
LTRN
$1.79
$0.021.13%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -63.29% | 26.62% | 30.65% | 7.29% | 12.67% |
| Total Depreciation and Amortization | 397.78% | 391.30% | -73.51% | 1,134.09% | 4.65% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 54,351.35% | 201.37% | -4.46% | 224.85% | -88.84% |
| Change in Net Operating Assets | -79.21% | -1,204.63% | -35.96% | 28.16% | 226.62% |
| Cash from Operations | 25.31% | 13.78% | 29.70% | 18.10% | 24.15% |
| Capital Expenditure | -- | -- | 100.00% | 80.00% | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -80.73% | 31.15% | -149.39% | 767.59% | 1,916.58% |
| Cash from Investing | -80.73% | 31.20% | -149.43% | 771.45% | 1,877.93% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | 7,998.33% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | 7,998.33% | -- |
| Foreign Exchange rate Adjustments | -102.51% | 528.57% | 104.46% | -101.85% | 146.90% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 651.04% | 143.67% | -570.37% | 147.77% | 94.12% |